|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sueblinvong T and Carney ME: Current
understanding of risk factors for ovarian cancer. Curr Treat
Options Oncol. 10:67–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gayther SA: Inherited risk of ovarian
cancer and the implications for screening. Int J Gynecol Cancer.
22((Suppl 1)): S12–S15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brekelmans CT: Risk factors and risk
reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol.
15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garland CF, Mohr SB, Gorham ED, Grant WB
and Garland FC: Role of ultraviolet B irradiance and vitamin D in
prevention of ovarian cancer. Am J Prev Med. 31:512–514. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maruotti N and Cantatore FP: Vitamin D and
the immune system. J Rheumatol. 37:491–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uitterlinden AG, Fang Y, Van Meurs JB,
Pols HA and Van Leeuwen JP: Genetics and biology of vitamin D
receptor polymorphisms. Gene. 338:143–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grant WB: Ecological studies of the
UVB-vitamin D-cancer hypothesis. Anticancer Res. 32:223–236.
2012.PubMed/NCBI
|
|
10
|
Daiger SP, Schanfield MS and
Cavalli-Sforza LL: Group-specific component (Gc) proteins bind
vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA.
72:2076–2080. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang L, Ma J, Zhang X, Fan Y and Wang L:
Protective role of the vitamin D receptor. Cell Immunol.
279:160–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Chalmers MJ, Stayrook KR, Burris
LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB,
Istrate MA, et al: DNA binding alters coactivator interaction
surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol.
18:556–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Larcombe L, Mookherjee N, Slater J,
Slivinski C, Singer M, Whaley C, Denechezhe L, Matyas S,
Turner-Brannen E, Nickerson P, et al: Vitamin D in a northern
Canadian first nation population: Dietary intake, serum
concentrations and functional gene polymorphisms. PLoS One.
7:e498722012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JJ, Wu X, Hildebrandt MA, Yang H,
Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, et al: Global
assessment of genetic variation influencing response to retinoid
chemoprevention in head and neck cancer patients. Cancer Prev Res
(Phila). 4:185–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pande M, Thompson PA, Do KA, Sahin AA,
Amos CI, Frazier ML, Bondy ML and Brewster AM: Genetic variants in
the vitamin D pathway and breast cancer disease-free survival.
Carcinogenesis. 34:587–594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prat J: FIGO Committee on Gynecologic
Oncology FIGO's staging classification for cancer of the ovary
fallopian tube, and peritoneum: Abridged republication. J Gynecol
Oncol. 26:87–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pludowski P, Holick MF, Pilz S, Wagner CL,
Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ,
Kienreich K, et al: Vitamin D effects on musculoskeletal health,
immunity, autoimmunity, cardiovascular disease, cancer, fertility,
pregnancy, dementia and mortality-a review of recent evidence.
Autoimmun Rev. 12:976–989. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Churilla TM, Brereton HD, Klem M and
Peters CA: Vitamin D deficiency is widespread in cancer patients
and correlates with advanced stage disease, A community oncology
experience. Nutr Cancer. 64:521–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Upadhyay SK, Verone A, Shoemaker S, Qin M,
Liu S, Campbell M and Hershberger PA: 1,25-Dihydroxyvitamin D3
(1,25(OH)2D3) signaling capacity and the epithelial-mesenchymal
transition in non-small cell lung cancer (NSCLC): Implications for
use of 1,25(OH)2D3 in NSCLC treatment. Cancers (Basel).
5:1504–1521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang JB, Abnet CC, Chen W, Dawsey SM, Fan
JH, Yin LY, Yin J, Major JM, Taylor PR, Qiao YL, et al: Association
between serum 25(OH) vitamin D, incident liver cancer and chronic
liver disease mortality in the Linxian Nutrition Intervention
Trials: A nested case-control study. Br J Cancer. 109:1997–2004.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yousef FM, Jacobs ET, Kang PT, Hakim IA,
Going S, Yousef JM, Al-Raddadi RM, Kumosani TA and Thomson CA:
Vitamin D status and breast cancer in Saudi Arabian women,
Case-control study. Am J Clin Nutr. 98:105–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roskies M, Dolev Y, Caglar D, Hier MP,
Mlynarek A, Majdan A and Payne RJ: Vitamin D deficiency as a
potentially modifiable risk factor for thyroid cancer. J
Otolaryngol Head Neck Surg. 41:160–163. 2012.PubMed/NCBI
|
|
23
|
Pereira F, Larriba MJ and Muñoz A: Vitamin
D and colon cancer. Endocr Relat Cancer. 19:R51–R71. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orell-Kotikangas H, Schwab U, Österlund P,
Saarilahti K, Mäkitie O and Mäkitie AA: High prevalence of vitamin
D insufficiency in patients with head and neck cancer at diagnosis.
Head Neck. 34:1450–1455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS,
Wang ZQ, Wang FH, Li YH, Zhou ZW and Xu RH: Prognostic effects of
25-hydroxyvitamin D levels in gastric cancer. J Transl Med.
10:162012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bakhru A, Mallinger JB, Buckanovich RJ and
Griggs JJ: Casting light on 25-hydroxyvitamin D deficiency in
ovarian cancer, A study from the NHANES. Gynecol Oncol.
119:314–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Merritt MA, Cramer DW, Vitonis AF, Titus
LJ and Terry KL: Dairy foods and nutrients in relation to risk of
ovarian cancer and major histological subtypes. Int J Cancer.
132:1114–1124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Walentowicz-Sadlecka M, Grabiec M,
Sadlecki P, Gotowska M, Walentowicz P, Krintus M, Mankowska-Cyl A
and Sypniewska G: 25(OH)D3 in patients with ovarian cancer and its
correlation with survival. Clin Biochem. 45:1568–1572. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kasiappan R, Shen Z, Tse AK, Jinwal U,
Tang J, Lungchukiet P, Sun Y, Kruk P, Nicosia SV, Zhang X, et al:
1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human
cancer growth through microRNA-498. J Biol Chem. 287:41297–41309.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pilon C, Urbanet R, Williams TA, Maekawa
T, Vettore S, Sirianni R, Pezzi V, Mulatero P, Fassina A, Sasano H,
et al: 1α,25-Dihydroxyvitamin D3 inhibits the human H295R cell
proliferation by cell cycle arrest: A model for a protective role
of vitamin D receptor against adrenocortical cancer. J Steroid
Biochem Mol Biol. 140:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kanemaru M, Maehara N and Chijiiwa K:
Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves
upregulation of cyclin-dependent kinase inhibitor p21 in human
pancreatic cancer cells. Hepatogastroenterology. 60:1199–1205.
2013.PubMed/NCBI
|
|
32
|
Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X,
Chen L, Zhou S, Goltzman D, Miao D, et al: 1, 25(OH)2D3 inhibits
hepatocellular carcinoma development through reducing secretion of
inflammatory cytokines from immunocytes. Curr Med Chem.
20:4131–4141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma Y, Yu WD, Su B, Seshadri M, Luo W,
Trump DL and Johnson CS: Regulation of motility, invasion, and
metastatic potential of squamous cell carcinoma by
1α,25-dihydroxycholecalciferol. Cancer. 119:563–574. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Swami S, Krishnan AV, Wang JY, Jensen K,
Horst R, Albertelli MA and Feldman D: Dietary vitamin D3 and
1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer
activity in mouse xenograft models of breast and prostate cancer.
Endocrinology. 153:2576–2587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Zhao CH, Zhang N and Wang J:
Vitamin D analog EB1089 induces apoptosis in a subpopulation of
SGC-7901 gastric cancer cells through a mitochondrial-dependent
apoptotic pathway. Nutr Cancer. 65:1067–1075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Nicosia SV and Bai W: Vitamin D
receptor is a novel drug target for ovarian cancer treatment. Curr
Cancer Drug Targets. 6:229–244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wolden-Kirk H, Gysemans C, Verstuyf A and
Mathieu C: Extraskeletal effects of vitamin D. Endocrinol Metab
Clin North Am. 41:571–594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mostowska A, Sajdak S, Pawlik P, Lianeri M
and Jagodzinski PP: Vitamin D receptor gene BsmI and
FokI polymorphisms in relation to ovarian cancer risk in the
Polish population. Genet Test Mol Biomarkers. 17:183–187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qin X, Lu Y, Qin A, Chen Z, Peng Q, Deng
Y, Xie L, Wang J, Li R, Zeng J, et al: Vitamin D receptor
BsmІ polymorphism and ovarian cancer risk: A meta-analysis.
Int J Gynecol Cancer. 23:1178–1183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clendenen TV, Arslan AA, Koenig KL,
Enquist K, Wirgin I, Agren A, Lukanova A, Sjodin H,
Zeleniuch-Jacquotte A, Shore RE, et al: Vitamin D receptor
polymorphisms and risk of epithelial ovarian cancer. Cancer Lett.
260:209–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tworoger SS, Gates MA, Lee IM, Buring JE,
Titus-Ernstoff L, Cramer D and Hankinson SE: Polymorphisms in the
vitamin D receptor and risk of ovarian cancer in four studies.
Cancer Res. 69:1885–1891. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song GG and Lee YH: Vitamin D receptor
FokI, BsmI, ApaI, and TaqI
polymorphisms and susceptibility to ovarian cancer: A
meta-analysis. Immunol Invest. 42:661–672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Y, Li C, Chen P, Li X, Li M, Guo H, Li
J, Chu R and Wang H: Polymorphisms in the vitamin D Receptor (VDR)
and the risk of ovarian cancer, A meta-analysis. PLoS One.
8:e667162013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Tong SC, Guan LH, Na F, Zhao W
and Wei L: Meta-analysis of the relation between vitamin D receptor
gene BsmI polymorphism and susceptibility to ovarian cancer.
Tumour Biol. 34:3317–3321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lurie G, Wilkens LR, Thompson PJ, McDuffie
KE, Carney ME, Terada KY and Goodman MT: Vitamin D receptor gene
polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol
Biomarkers Prev. 16:2566–2571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mohapatra S, Saxena A, Gandhi G, Koner BC
and Ray PC: Vitamin D and VDR gene polymorphism (FokI) in
epithelial ovarian cancer in Indian population. J Ovarian Res.
6:372013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lurie G, Wilkens LR, Thompson PJ, Carney
ME, Palmieri RT, Pharoah PD, Song H, Hogdall E, Kjaer SK, DiCioccio
RA, et al: Ovarian Cancer Association Consortium: Vitamin D
receptor rs2228570 polymorphism and invasive ovarian carcinoma
risk: Pooled analysis in five studies within the Ovarian Cancer
Association Consortium. Int J Cancer. 128:936–943. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li S, Xu H, Li SC, Qi XQ and Sun WJ:
Vitamin D receptor rs2228570 polymorphism and susceptibly to
ovarian cancer, a meta-analysis. Tumour Biol. 35:1319–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Luo XY, Yang MH, Wu FX, Wu LJ, Chen L,
Tang Z, Liu NT, Zeng XF, Guan JL and Yuan GH: Vitamin D receptor
gene BsmI polymorphism B allele, but not BB genotype, is
associated with systemic lupus erythematosus in a Han Chinese
population. Lupus. 21:53–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Arai H, Miyamoto K, Taketani Y, Yamamoto
H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S and Takeda E: A
vitamin D receptor gene polymorphism in the translation initiation
codon, Effect on protein activity and relation to bone mineral
density in Japanese women. J Bone Miner Res. 12:915–921. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Monticielo OA, Brenol JC, Chies JA, Longo
MG, Rucatti GG, Scalco R and Xavier RM: The role of BsmI and
FokI vitamin D receptor gene polymorphisms and serum
25-hydroxyvitamin D in Brazilian patients with systemic lupus
erythematosus. Lupus. 21:43–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gozdzik A, Zhu J, Wong BY, Fu L, Cole DE
and Parra EJ: Association of vitamin D binding protein (VDBP)
polymorphisms and serum 25(OH)D concentrations in a sample of young
Canadian adults of different ancestry. J Steroid Biochem Mol Biol.
127:405–412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jacobs ET, Martínez ME, Campbell PT, Conti
DV, Duggan D, Figueiredo JC, Haile RW, LeRoy EC, Poynter JN,
Thompson PA, et al: Genetic variation in the retinoid X receptor
and calcium-sensing receptor and risk of colorectal cancer in the
Colon Cancer Family Registry. Carcinogenesis. 31:1412–1416. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Karami S, Brennan P, Rosenberg PS,
Navratilova M, Mates D, Zaridze D, Janout V, Kollarova H, Bencko V,
Matveev V, et al: Analysis of SNPs and haplotypes in vitamin D
pathway genes and renal cancer risk. PLoS One. 4:e70132009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Egan JB, Thompson PA, Ashbeck EL, Conti
DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D,
et al: Genetic polymorphisms in vitamin D receptor VDR/RXRA
influence the likelihood of colon adenoma recurrence. Cancer Res.
70:1496–1504. 2010. View Article : Google Scholar : PubMed/NCBI
|
